Welcome to our dedicated page for Liquidia news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia stock.
Liquidia Corporation develops and commercializes therapies for respiratory and vascular diseases, with a focus on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its updates center on YUTREPIA® (treprostinil) inhalation powder, the company’s PRINT® Technology-enabled approved therapy, along with L606, an investigational extended-release treprostinil formulation administered with a nebulizer, and generic Treprostinil Injection for PAH.
Recurring news includes financial results, YUTREPIA commercial uptake, clinical data presentations, pipeline studies, corporate presentations and investor conference participation. Company updates also discuss treprostinil delivery, PAH and PH-ILD treatment settings, cash generation and profitability as product sales become a larger part of Liquidia’s operating profile.
Liquidia Corporation (LQDA) announced that the addressable market for generic Treprostinil Injection has more than doubled following FDA clearance of the RG 3ml Medication Cartridge for use with the CADD-MS® 3 pump. This breakthrough allows Treprostinil to be administered subcutaneously, expanding patient access for pulmonary arterial hypertension (PAH) treatment. The cartridge enables the first subcutaneous administration of the generic drug, previously limited to intravenous use.
Liquidia Corporation (NASDAQ: LQDA) reported its financial results for 2020, revealing a significant decrease in revenue to $0.7 million from $8.1 million in 2019. The company's net loss grew to $59.8 million, or $1.76 per share. Financial measures include a more than 40% reduction in annual cash spending planned for 2021, and a confirmed path to submit a response to the Complete Response Letter (CRL) for LIQ861 in mid-2021. Following the integration of RareGen, Liquidia aims to strengthen its commercial presence in pulmonary arterial hypertension (PAH). Cash reserves were at $65.3 million as of year-end 2020.
Liquidia Corporation (NASDAQ: LQDA) will announce its 2020 financial results on March 23, 2021, followed by a webcast and conference call at 8:30 a.m. ET. The call can be accessed via phone or through their website. Liquidia specializes in developing treatments for pulmonary hypertension and other applications using its PRINT technology. Its key product candidates include LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain management.
Liquidia Corporation (NASDAQ: LQDA) announced the closing of a debt facility with Silicon Valley Bank, providing up to $20.5 million in loans. The initial tranche of $10.5 million has been funded and used to retire existing debt, adding $1 million to Liquidia’s balance sheet. The second tranche of $5 million is contingent on FDA tentative approval for LIQ861 by June 30, 2022, and the final tranche is available upon full approval by December 31, 2022. The facility matures on September 1, 2024, with interest-only payments through March 31, 2023.
Liquidia Corporation (NASDAQ: LQDA) has appointed Damian deGoa as the new CEO, effective immediately, succeeding Neal F. Fowler, who has retired. DeGoa brings extensive healthcare experience, particularly in pulmonary arterial hypertension (PAH). Under his leadership, Liquidia aims to address regulatory concerns for LIQ861, a drug recently acquired from RareGen. The CEO's stock option grant includes 2 million shares, with specific vesting conditions tied to regulatory and commercial milestones.
Liquidia Corporation (NASDAQ: LQDA) has appointed Michael Kaseta as the new Chief Financial Officer (CFO) effective immediately, succeeding Steve Bariahtaris, the interim CFO since August 2020. Kaseta brings extensive experience from his previous CFO roles at Aerami Therapeutics and Aralez Pharmaceuticals, as well as over a decade at Sanofi. CEO Neal Fowler expressed confidence in Kaseta's ability to aid in Liquidia's growth strategy, especially with products like LIQ861 and RareGen on the horizon.
Liquidia Technologies announced a complete response letter (CRL) from the FDA regarding its NDA for LIQ861, an inhalation powder for pulmonary arterial hypertension (PAH). The CRL requests additional information on chemistry, manufacturing, and controls (CMC) and device biocompatibility but does not require new clinical studies. Liquidia expects to resolve these issues without delaying LIQ861's projected launch in H2 2022. Liquidia remains confident in LIQ861's potential to improve treatment options for PAH patients, supported by positive clinical trial results.
Liquidia Corporation has successfully completed its acquisition of RareGen, LLC, reinforcing its commitment to the pulmonary arterial hypertension (PAH) community. The all-stock merger, valued at 5,550,000 shares, positions Liquidia to enhance its offerings in the PAH market, particularly with the potential approval of LIQ861. The merger adds experienced board members Paul Manning and Roger Jeffs, signaling a strategic move towards growth. Liquidia Technologies stockholders will receive shares in the new Liquidia Corporation, which will trade under the ticker symbol 'LQDA' starting November 19, 2020.
Liquidia Technologies (NASDAQ: LQDA) has received stockholder approval for its merger with RareGen, LLC. The vote occurred on November 13, 2020, with approximately 71% of outstanding shares endorsing the Merger Agreement. This merger is anticipated to close on or about November 18, 2020. Post-merger, both companies will operate as wholly owned subsidiaries of Liquidia Corporation. Additionally, stockholders approved two plans for employee incentives effective upon merger completion.
Liquidia Technologies (Nasdaq: LQDA) announced that CEO Neal Fowler will present at the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020, at 7:55 PM GMT. The presentation will be available via a live audio webcast, with a replay accessible for at least 90 days. Liquidia is focused on developing innovative products using its proprietary PRINT® technology, particularly two candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain relief.